These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 34611418)

  • 1. An Open-Label, Randomized, Double-Arm Clinical Trial to Compare the Effectiveness and Safety of Super Bioavailable Itraconazole Capsules and Itraconazole Capsules in the Management of Dermatophytosis in India.
    Shenoy M; Dhoot D; Mahajan H; Barkate H
    Clin Cosmet Investig Dermatol; 2021; 14():1367-1376. PubMed ID: 34611418
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetic and clinical comparison of super-bioavailable itraconazole and conventional itraconazole at different dosing in dermatophytosis.
    Dhoot D; Jain GK; Manjhi M; Kesharwani P; Mahadkar N; Barkate H
    Drugs Context; 2023; 12():. PubMed ID: 36660014
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of Super-Bioavailable Itraconazole and Conventional Itraconazole at Different Dosing Regimens in Glabrous Tinea Infection - A Randomized Clinical Trial.
    Shenoy MM; De A; Shah B; Das A; Saraswat A; Lahiri K; Yadav S; Sarda A; Chakraborty D; J D; Kamat S; Doshi Y; Gonsalves N; Choudhary A; Dhoot D; Mahadkar N; Bhushan S; Gadkari R; Barkate H
    Drug Des Devel Ther; 2023; 17():2899-2908. PubMed ID: 37766823
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical Use of Super-Bioavailable Itraconazole for the Management of Dermatophytosis: Consensus Statement by Dermatologists from India via the Modified Delphi Technique.
    Saraswat A; Dogra S; Shenoy M; Verma S; K S; Ghate S; Ganjoo A; Aurangabadkar S; Tiwari A; Poojary S; Inamdar A; Majid I; Girdhar M; Shah B; Varma S; Ramamoorthy R; Dhoot D; Barkate H
    Dermatology; 2024; 240(4):671-683. PubMed ID: 38697027
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative Efficacy of Super Bioavailable Itraconazole Capsules 50 mg vs 65 mg Twice Daily in the Management of Glabrous Tinea.
    Shah B; Mistry D; Jairam D; Kansara K; Pandya R; Vasani P; Dhoot D; Mahadkar N; Bhushan S; Barkate H
    Infect Drug Resist; 2023; 16():2409-2416. PubMed ID: 37125212
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Limited effectiveness of four oral antifungal drugs (fluconazole, griseofulvin, itraconazole and terbinafine) in the current epidemic of altered dermatophytosis in India: results of a randomized pragmatic trial.
    Singh S; Chandra U; Anchan VN; Verma P; Tilak R
    Br J Dermatol; 2020 Nov; 183(5):840-846. PubMed ID: 32538466
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative Efficacy and Safety of Super-Bioavailable Itraconazole-130 mg Once Daily in Obese and Non-Obese Patients of Glabrous Tinea.
    Shenoy M; De A; Shah B; Das A; Saraswat A; Lahiri K; Dhoot D
    Indian Dermatol Online J; 2023; 14(6):839-843. PubMed ID: 38099030
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of efficacy and safety of oral terbinafine and itraconazole combination therapy in the management of dermatophytosis.
    Sharma P; Bhalla M; Thami GP; Chander J
    J Dermatolog Treat; 2020 Nov; 31(7):749-753. PubMed ID: 31030594
    [No Abstract]   [Full Text] [Related]  

  • 9. Correlation of plasma levels of itraconazole with treatment response at 4 weeks in chronic dermatophytosis: Results of a randomised controlled trial.
    Bhalavi H; Shaw D; Mehta H; Narang T; Sachdeva N; Shafiq N; Rudramurthy SM; Dogra S
    Mycoses; 2023 Apr; 66(4):281-288. PubMed ID: 36457207
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of Different Itraconazole Dosing Regimens on Cure Rates, Treatment Duration, Safety, and Relapse Rates in Adult Patients With Tinea Corporis/Cruris: A Randomized Clinical Trial.
    Khurana A; Agarwal A; Agrawal D; Panesar S; Ghadlinge M; Sardana K; Sethia K; Malhotra S; Chauhan A; Mehta N
    JAMA Dermatol; 2022 Sep; 158(11):1269-78. PubMed ID: 36103158
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Super Bioavailable Itraconazole and Its Place and Relevance in Recalcitrant Dermatophytosis: Revisiting Skin Levels of Itraconazole and Minimum Inhibitory Concentration Data.
    Sardana K; Mathachan SR
    Indian Dermatol Online J; 2021; 12(1):1-5. PubMed ID: 33768016
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Itraconazole in the treatment of tinea corporis and tinea cruris: comparison of two treatment schedules.
    Boonk W; de Geer D; de Kreek E; Remme J; van Huystee B
    Mycoses; 1998 Dec; 41(11-12):509-14. PubMed ID: 9919895
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Indian Association of Dermatologists, Venereologists and Leprologists (IADVL) Task Force against Recalcitrant Tinea (ITART) Consensus on the Management of Glabrous Tinea (INTACT).
    Rengasamy M; Shenoy MM; Dogra S; Asokan N; Khurana A; Poojary S; Jayaraman J; Valia AR; Sardana K; Kolalapudi S; Marfatia Y; Rao PN; Bhat RM; Kura M; Pandhi D; Barua S; Kaushal V
    Indian Dermatol Online J; 2020; 11(4):502-519. PubMed ID: 32832435
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of the benefit of the addition of 1% topical luliconazole versus topical bland emollient to the systemic itraconazole therapy for the management of disseminated dermatophytosis: A randomised control trial.
    Rana DK; Shah TS; Rohit MH; Patel NH; Khadela AD; Oza YP; Padhiyar JK
    Mycoses; 2024 Jan; 67(1):e13681. PubMed ID: 38214352
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Voriconazole is superior to combined itraconazole/isotretinoin therapy and itraconazole monotherapy in recalcitrant dermatophytosis.
    Khattab F; Elkholy BM; Taha M; Abd-Elbaset A; Fawzy M
    Mycoses; 2022 Dec; 65(12):1194-1201. PubMed ID: 35943822
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Double-blind comparison of itraconazole and placebo in the treatment of tinea corporis and tinea cruris.
    Pariser DM; Pariser RJ; Ruoff G; Ray TL
    J Am Acad Dermatol; 1994 Aug; 31(2 Pt 1):232-4. PubMed ID: 8040406
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Itraconazole compared with griseofulvin in the treatment of tinea corporis/cruris and tinea pedis/manus: an interpretation of the clinical results of all completed double-blind studies with respect to the pharmacokinetic profile.
    Lachapelle JM; De Doncker P; Tennstedt D; Cauwenbergh G; Janssen PA
    Dermatology; 1992; 184(1):45-50. PubMed ID: 1313717
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical experience with short schedules of itraconazole in the treatment of tinea corporis and/or tinea cruris.
    Parent D; Decroix J; Heenen M
    Dermatology; 1994; 189(4):378-81. PubMed ID: 7873824
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of oral terbinafine versus itraconazole in treatment of dermatophytic infection of skin - A prospective, randomized comparative study.
    Bhatia A; Kanish B; Badyal DK; Kate P; Choudhary S
    Indian J Pharmacol; 2019; 51(2):116-119. PubMed ID: 31142947
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Clinical study of itraconazole for the treatment of Tinea cruris, Tinea corporis and Tinea pedis interdigital].
    Zaitz C; Ruiz LR; Drullis EM; Gurfinkel P; Ciarnuto MA
    Rev Inst Med Trop Sao Paulo; 1990; 32(4):299-303. PubMed ID: 1966257
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.